On April 28, 2022 Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, reported that it will report first quarter 2022 financial results after the U.S. financial markets close on Thursday, May 5, 2022 (Press release, Oncternal Therapeutics, APR 28, 2022, View Source [SID1234613145]). Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast of the call will be available online at investor.oncternal.com and the call will be archived there for at least 30 days.

On April 28, 2022 Merck & Co reported its first quarter 2022 results (Presentation, Merck & Co, APR 28, 2022, View Source [SID1234613162]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 28, 2022 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that its management team will present at the following investor conferences (Press release, Personalis, APR 28, 2022, View Source [SID1234613178]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bank of America 2022 Healthcare Conference
Presenting on Wednesday, May 11, 2022 at 6:20 p.m. Eastern Time at the Encore Hotel in Las Vegas
A live audio webcast and replay of the presentation may be accessed for 90 days on the "Investors" section of the company’s website at: View Source
UBS Global Healthcare Conference 2022
Presenting on Tuesday, May 24, 2022 at 3:30 p.m. Eastern Time at the Lotte New York Palace Hotel in New York

On April 26, 2022 Argonaut Therapeutics, a leading developer of novel cancer agents, reported a company showcase presentation at the BioTrinity 2022 event, an international conference focused on bio-partnering and investment (Press release, Argonaut Therapeutics, APR 28, 2022, View Source [SID1234613196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation to an audience of key industry investors and experts highlighted Argonaut Therapeutics vision to become a leading company in delivering innovative treatments to treat deadly cancers and provided an overview of the company’s proprietary assets and platforms, with an expanded focus on novel drug targets discovered in cancer relevant pathways.

About BioTrinity

BioTrinity is an established, must-attend London conference, that catalyses growth and supports in- person re-engagement across the life sciences industry. The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:

"Arginine methylation is an extremely important process under aberrant control in many different cancers and drugs targeting arginine methylation will find clinical utility in diverse indications. We are delighted to have been invited to present in the oncology session at the BioTrinity 2022 event and share details on Argonaut’s novel and exciting asset pipeline".

Listen to Argonaut’s BioTrinity 2022 presentation here

On April 28, 2022 Vivesto AB, an oncology-focused specialty pharmaceutical company, reported that the Annual Report for 2021 has been published (Press release, Vivesto, APR 28, 2022, View Source [SID1234613092]). The Annual Report is attached as a PDF and is available on the company’s website, View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!